Form 4: ImmunityBio CFO Sachs Reports RSU Vesting & Share Disposition
Insider Transaction Report
ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting of restricted stock units and subsequent disposition of shares for tax withholding.
Summary
- David C. Sachs, Chief Financial Officer of ImmunityBio, Inc., reported changes in his beneficial ownership of company securities.
- On December 31, 2025, 30,397 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 30,397 shares of common stock at a price of $0.
- Concurrently, 15,435 shares of common stock were disposed of on December 31, 2025, at a price of $1.98 per share to satisfy tax withholding obligations related to the RSU vesting.
- The closing price of ImmunityBio, Inc.'s common stock on December 30, 2025, which was $1.98, was used to calculate the shares withheld for taxes.
- Following these transactions, Sachs directly beneficially owns 240,582 shares of common stock and 45,602 Restricted Stock Units.
- A Power of Attorney was executed on October 6, 2025, authorizing designated individuals to prepare and file SEC reports on Sachs' behalf.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of an insider's equity compensation vesting and tax-related share disposition, which is neutral in sentiment. It provides transparency but no new positive or negative operational or financial news.
Future Outlook
The filing indicates a future RSU vesting event scheduled for December 31, 2026, for the remaining restricted stock units held by David C. Sachs.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of restricted stock units and subsequent tax-related share disposition. Such transactions are common across all industries for executives receiving equity compensation and do not inherently reflect broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive equity compensation and ownership changes, which is standard for public companies.
- Employees: No direct impact on general employees.
- Customers/Suppliers/Creditors: No direct impact.
Next Steps
- The remaining Restricted Stock Units held by David C. Sachs are scheduled to vest on December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 2021-09-09 | Five percent (5%) of 151,989 RSUs vested. |
| 2021-12-09 | 17,242 RSUs vested. |
| 2022-12-31 | Five percent (5%) of RSUs vested. |
| 2023-12-31 | Twenty percent (20%) of RSUs vested. |
| 2024-12-31 | Twenty percent (20%) of RSUs vested. |
| 2025-10-06 | Power of Attorney executed by David C. Sachs. |
| 2025-12-30 | Closing price of ImmunityBio common stock ($1.98) used for tax withholding calculation. |
| 2025-12-31 | Transaction date for RSU vesting and share disposition; twenty percent (20%) of RSUs vested. |
| 2026-01-05 | Form 4 filing date. |
| 2026-12-31 | Remaining RSUs are scheduled to vest. |
Keywords
ImmunityBio, IBRX, David C. Sachs, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Share Disposition, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.